Survivin and GRP-78 are considered as critical factors to mediate the drug resistance on HepJ5 cells with gemcitabine and sorafenib treatments [22, 28], which inhibit caspase-3 associated cell death on tumor cells [29, 30]. The gene discussed is BIRC5; the disease is neoplasm.